Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
06/27/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
05/13/2021 | 2021.21% | Ladenburg Thalmann | → $35 | Initiates Coverage On | → Buy |
4d pharma Questions & Answers
The latest price target for 4d pharma (NASDAQ: LBPS) was reported by Chardan Capital on June 27, 2022. The analyst firm set a price target for $0.00 expecting LBPS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for 4d pharma (NASDAQ: LBPS) was provided by Chardan Capital, and 4d pharma downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4d pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4d pharma was filed on June 27, 2022 so you should expect the next rating to be made available sometime around June 27, 2023.
While ratings are subjective and will change, the latest 4d pharma (LBPS) rating was a downgraded with a price target of $0.00 to $0.00. The current price 4d pharma (LBPS) is trading at is $1.65, which is out of the analyst's predicted range.